/
•
•
Context is everything.
Detailed stories on technology startups, business and economic current affairs.
Detailed stories on technology startups, business and economic current affairs.
CEO Rajeev Nannapaneni’s oft-used strategy of mounting patent challenges in the US got the pharma company its latest blockbuster Revlimid. But what after sales fall off a cliff?
CEO Rajeev Nannapaneni’s oft-used strategy of mounting patent challenges in the US got the pharma company its latest blockbuster Revlimid. But what after sales fall off a cliff?
The drugmaker’s reluctance to part with cash may have given it one of the strongest balance sheets in Indian pharma, but investors are increasingly rewarding risk takers.
The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.
The rules require exporters of certain drugs to get an NOC from importing countries—a small but much-needed step to restoring India’s credibility in the global pharma market.
The drugmaker’s reluctance to part with cash may have given it one of the strongest balance sheets in Indian pharma, but investors are increasingly rewarding risk takers.
The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.
The rules require exporters of certain drugs to get an NOC from importing countries—a small but much-needed step to restoring India’s credibility in the global pharma market.
